Continuous low-dose oral chemotherapy in recurrent and persistent carcinoma of cervix following chemoradiation: A comparative study between prolonged oral cyclophosphamide and oral etoposide

Autor: Pankaj Deka, Sushruta Shrivastava, Debabrata Barmon, Upasana Baruah, Munlima Hazarika, Amal Chandra Kataki
Rok vydání: 2014
Předmět:
Hospice care
Culture
Position statement
Gastroenterology
Head and neck cancers
Oral transmucosal fentanyl citrate
Ethnicity
Cancer
Cervical cancer
lcsh:R5-920
Morphine
Health Policy
Oral cyclophosphamide
Low dose
Breakthrough cancer pain
National standards
Quality assurance
medicine.anatomical_structure
Palliative care
Symptom burden
Original Article
End of life care
lcsh:Medicine (General)
Oral etoposide
medicine.drug
Quality of life
Recurrent carcinoma cervix
Numeric rating scale
medicine.medical_specialty
Cyclophosphamide
Pain
India
Metronomic therapy
Neutropenia
Limited resources
Developing countries
Internal medicine
medicine
Carcinoma
Indian association of palliative care
Quality improvement
Cervix
business.industry
Public Health
Environmental and Occupational Health
Audit
medicine.disease
Surgery
business
Zdroj: Indian Journal of Palliative Care, Vol 20, Iss 3, Pp 208-211 (2014)
Indian Journal of Palliative Care
ISSN: 0973-1075
DOI: 10.4103/0973-1075.138396
Popis: Aim: To compare the efficacy and toxicities of low-dose oral cyclophosphamide and oral etoposide in patients with persistent and recurrent cervical cancer with gross pelvic disease following full course of chemoradiation therapy. Materials and Methods: 30 patients with recurrent and persistent cervical cancer with gross pelvic disease were enrolled in this trial. The patients were randomly divided into two groups of 15 patients each with one group receiving low dose oral cyclophosphamide (100 mg/day) and the other group receiving low-dose oral etoposide (50 mg/day). Results were statistically analysed by IBM SPSS Statistics 19. Results: Oral etoposide was not well tolerated with grade 2 neutropenia occurring in 33.3% and grade 3 neutropenia in 6.6% and thrombocytopenia occurring in 13.3%. Oral cyclophosphamide group on the other hand was better tolerated with none of the patients having thrombocytopenia and 6.6% patients having grade 2 neutropenia. There were two complete response (15.38%) and one partial response at the end of study (7.6%) in the cyclophosphamide group whereas there was no complete response and two partial response (16.6%) in the oral etoposide group. Conclusion: Long-term, low-dose oral etoposide was found to be less tolerated without any significant effect with patients with persistent and recurrent cervical cancer with gross pelvic disease following full course of chemoradiation therapy in contrast to oral cyclophosphamide which was found to be effective and well-tolerated by the patients.
Databáze: OpenAIRE
Externí odkaz: